In fact, to effectively suppress BRAF or KRAS in metastatic CRCs brought on by activating mutations in these genes, a combination of drugs is required that block the mutant protein while also limiting adaptive resistance through CRC-specific EGFR-mediated feedback loops. This evidence concerns the gene EGFR and colorectal carcinoma.